Synaptogenix Inc (SNPX)

[InTheTrenches]

IMO, the fact that the news is on Monday morning is positive, and I agree it increases the chances of great news, good news or barely missed primary endpoint (but probably made some of the secondary endpoints). Thanks Flash for getting IR to do their job, and give us a heads-up this morning.

The thing I'm most anxious about for Monday's release is how many patients dropped out. As Flash has pointed out, this can skew results unexpectedly. In our case, it may cause p-values to LOOK disappointing, when they're not. However, if there is significant SIB improvement in those on-drug patients that complete the trial, we can still get successful p-values.

Watch carefully the secondary endpoints. Other drugs don't seem to have any effect on the activities of daily living (ADLs) in moderate-to-severe AD patients. Our compassionate-use patients did astoundingly well in the ADLs (anecdotal), so if there's something significant in the secondary endpoints, big pharma/biotech will be VERY, VERY interested, even if the SIB scores barely miss.

Finally, look close at the 17-week test scores vs. the 12-week test scores. Dr. Alkon stated at the Sach's conference (late March) that they have reason to believe that Bryostatin has a residual effect. This is our first glimpse at their theory of residual effect.

Good luck to all longs!